Browse

You are looking at 351 - 400 of 871 items for :

  • Educational & Training x
  • Refine by Access: All content x
Clear All
Restricted access
Cover The Pharmacist’s Guide to Opioid Use Disorders

The Pharmacist’s Guide to Opioid Use Disorders

Edited by Merrill Norton, Jeffrey N. Baldwin, and Michael G. O’Neil

Restricted access

1. Introduction to Anticoagulation Management

William E. Dager, Michael P. Gulseth, and Edith A. Nutescu

Restricted access

10. Transitions in Care—Periprocedural Bridging and Transitions Between Agents

Jessica Rimsans, Katelyn W. Sylvester, and John Fanikos

Restricted access

11. Considerations in Special Populations

Thaddaus Hellwig and William E. Dager

Restricted access

12. Venous Thromboembolism Prevention

Paul P. Dobesh and Kelsey Aker

Restricted access

13. Venous Thromboembolism Treatment

Snehal H. Bhatt and Michael P. Gulseth

Restricted access

14. Atrial Fibrillation

Daniel M. Witt

Restricted access

15. Acute Coronary Syndromes

Sarah A. Spinler

Restricted access

16. Prosthetic Heart Valves

Douglas C. Anderson

Restricted access

17. Mechanical Circulatory Support Devices

Christopher Paciullo, Laura Baumgartner, and Lauren Roller

Restricted access

18. Heparin-Induced Thrombocytopenia

William E. Dager

Restricted access

19. Pregnancy

Nancy L. Shapiro

Restricted access

2. Warfarin

Ann K. Wittkowsky

Restricted access

20. Pediatrics

Kirsten H. Ohler

Restricted access

21. Coagulation Laboratory Considerations

Robert C. Gosselin and Maureen A. Smythe

Restricted access

22. Thrombophilias

Jessica B. Michaud and Canice A. Coan

Restricted access

23. Models and Standards of Anticoagulation Care Delivery

Nathan P. Clark and Paul B. Shaw

Restricted access

24. Regulatory and Practice Resources

Michael P. Gulseth and William E. Dager

Restricted access

3. Unfractionated Heparin

William E. Dager

Restricted access

4. Low Molecular Weight Heparin and Fondaparinux

Zachary Stacy and Sara K. Richter

Restricted access

5. Parenteral Direct Thrombin Inhibitors

William E. Dager and A. Joshua Roberts

Restricted access

6. Thrombolytic Considerations When Used with Anticoagulants

Toby C. Trujillo and Tyree H. Kiser

Restricted access

7. Direct Oral Anticoagulants

Allison E. Burnett and Candice L. Garwood

Restricted access

8. Anticoagulation Reversal: Part I—Pharmacology of Agents Used for Reversal

Lance J. Oyen and Scott A. Chapman

Restricted access

9. Anticoagulation Reversal: Part II—Clinical Application

William E. Dager

Restricted access
Cover Anticoagulation Therapy

Anticoagulation Therapy

A Clinical Practice Guide

Edited by William E. Dager, Michael P. Gulseth, and Edith A. Nutescu

Restricted access

Chapter 1: Introduction to Opioid Conversion Calculations

Edited by Mary Lynn McPherson

Restricted access

Chapter 2: Converting Among Routes and Formulations of the Same Opioid

Edited by Mary Lynn McPherson

Restricted access

Chapter 3: Converting Among Routes and Formulations of Different Opioids

Edited by Mary Lynn McPherson

Restricted access

Chapter 4: Titrating Opioid Regimens: Around the Clock and to the Rescue!

Edited by Mary Lynn McPherson

Restricted access

Chapter 5: Transdermal and Parenteral Fentanyl Dosage Calculations and Conversions

Edited by Mary Lynn McPherson

Restricted access

Chapter 6: Methadone: A Complex and Challenging Analgesic, But It’s Worth It!

Edited by Mary Lynn McPherson

Restricted access

Chapter 7: Patient-Controlled Analgesia and Neuraxial Opioid Therapy

Edited by Mary Lynn McPherson

Restricted access

Chapter 8: Calculating Doses from Oral Solutions and Suspensions

Edited by Mary Lynn McPherson

Restricted access

Chapter 9: Lagniappe: A Little Something Extra in Conversion Calculations

Edited by Mary Lynn McPherson

Restricted access
Cover Demystifying Opioid Conversion Calculations

Demystifying Opioid Conversion Calculations

A Guide for Effective Dosing

Edited by Mary Lynn McPherson

Restricted access
Cover Biosimilars & Biologics

Biosimilars & Biologics

Implementation and Monitoring in a Healthcare Setting

Edited by Steven Lucio

Restricted access

Chapter 1: A New Type of Blockbuster: The Growth of Biologics

Edited by Steven Lucio

Restricted access

Chapter 10: Defining Biosimilar Value and Other Seemingly Impossible Tasks

Edited by Steven Lucio

Restricted access

Chapter 11: Biosimilar Formulary Management Strategies

Edited by Steven Lucio

Restricted access

Chapter 2: Déjà Vu or Something New?–Comparing the Generic and Biosimilar Experiences

Edited by Steven Lucio

Restricted access

Chapter 3: Bugs and Drugs, and Yeast and Mice, and Chinese Hamsters

Edited by Steven Lucio

Restricted access

Chapter 4: The $250 Billion Pyramid: Analytics in Biosimilarity Determination

Edited by Steven Lucio

Restricted access

Chapter 5: The Global Biosimilars Experience

Edited by Steven Lucio

Restricted access

Chapter 6: The American Biosimilar Experience: Red, White, and Possibly Interchangeable

Edited by Steven Lucio

Restricted access

Chapter 7: Biosimilar Clinical Trial Requirements

Edited by Steven Lucio

Restricted access

Chapter 8: Immunogenicity and Pharmacovigilance in the Biosimilar Era

Edited by Steven Lucio

Restricted access

Chapter 9: The Patent Dance and the Exclusivity Shuffle

Edited by Steven Lucio

Restricted access

Conclusion: Biosimilars 2023

Edited by Steven Lucio

Restricted access

Appendix A: Prescription and Medication Orders

Edited by Nicholas Ferencz